celebra 100 mg
upjohn eesv - celekoksib - kapsel, hard - 100 mg
celebra 200 mg
upjohn eesv - celekoksib - kapsel, hard - 200 mg
celebrex 200 mg
2care4 aps - celekoksib - kapsel, hard - 200 mg
celebrex 200 mg
orifarm as - celekoksib - kapsel, hard - 200 mg
celebrex 100 mg
orifarm as - celekoksib - kapsel, hard - 100 mg
celebrex 200 mg
2care4 aps - celekoksib - kapsel, hard - 200 mg
celebrex 100 mg
2care4 aps - celekoksib - kapsel, hard - 100 mg
celebra 200 mg
farmagon - celekoksib - kapsel, hard - 200 mg
celebra 200 mg
farmagon - celekoksib - kapsel, hard - 200 mg
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.